Metabolic meds startup Verdiva launches with $411M

The latest stories trending on MedCity News.

Editor's Pick

Top Story Metabolic Meds Startup Verdiva Launches With $411M and a Weekly Oral GLP-1 Drug Verdiva Bio's once-a-week oral GLP-1 drug is ready for Phase 2 testing. The drug, made with a proprietary technology that enables oral dosing, was licensed from Sciwind Biosciences.

Featured News

Innovaccer Rakes In $275M, Kicking Off What Will Likely Be Another Hot Year for AI Funding Healthcare AI company Innovaccer closed a $275 million Series F funding round, bringing its fundraising total to date to $675 million. The company has plans to go public "at some point," but it isn't in any hurry, said CEO Abhinav Shashank. Twentyeight Health Raises $10M, Secures New Medicaid Partnerships Twentyeight Health's $10 million Series A round was led by Seae Ventures and included participation from Impact America Fund, The Social Entrepreneurs' Fund, RH Capital, Impact Engine, Gratitude Railroad and Townhall Ventures. What AI Can Do for Pharmacist Burnout AI offers a number of immediate opportunities for pharmacies to change their operation through intelligent automation, freeing up pharmacists to provide their patient population with higher-value services like patient counseling and medication management. The People Behind America's Health With the election behind us, it's time to lift healthcare above campaign rhetoric and invest in a care economy that breaks the cycle of chronic illness to build longer, healthier lives for all Americans.

Resources

MedCity Pivot: A Chat with Accolade's Chief Health Officer Dr. Shantanu Nundy describes how care navigation company Accolade can help self-insured employers lower costs for providing health coverage to their employees. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe